Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Longeveron Inc.

NASDAQ: LGVN · Life Sciences · 7 alerts · CIK 1721484

Share price
$2.14Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Longeveron Inc. filings on SEC EDGAR ↗

4:45 PM ET 8-K
Clinical Trial Data

Longeveron Clinical Trial Data

Longeveron announced updated Phase 2b ELPIS II trial results for laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial missed its primary efficacy endpoint of RVEF change, additional analysis showed the secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance with only 1 event in the treatment arm versus 8 in the standard of care arm (P=0.043).

Counterparty
National Institutes of Health (NIH)
4:02 PM ET 8-K
Clinical Trial Data

Longeveron Clinical Trial Data

Longeveron announced that its Phase 2b ELPIS II trial evaluating laromestrocel for hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint of change in right ventricular ejection fraction at 12 months. Despite the failure, the company noted a favorable safety profile and plans to discuss exploratory clinical outcomes with the FDA to determine potential next steps. Consequently, the company has initiated cost containment measures and is exploring options to maximize shareholder value.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.